Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control
NCT ID: NCT00701831
Last Updated: 2010-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
241 participants
INTERVENTIONAL
2008-05-31
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To observe the efficacy of the forced titration to reach good glycemic control in Lantus treated patients
Secondary objectives:
* To assess the forced titration on physician and patient satisfaction
* To evaluate the impact of training tools by means of patient profile
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Insulin glargine
Insulin glargine
The dose is titrated according to patient needs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Insulin glargine
The dose is titrated according to patient needs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients whom their physician is considering initiation of Lantus treatment
* Poor glycemic control 7,5 %10 %
* T2 treatment with OADs more than 3 months
* BMI\<40 kg/m2
Exclusion Criteria
* Acute or chronic metabolic acidosis
* Active liver disease or serum ALT or AST \>2,5 than normal
* History of hypoglycemia unawareness
* Diabetic retinopathy with surgery in the previous 3 months or planned within 3 months after study entry
* Pregnancy, breast feeding
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zeynep Cetin
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sanofi-Aventis Administrative Office
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LANTU_L_03502
Identifier Type: -
Identifier Source: org_study_id